Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics and Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Pasadena, California.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Latest Biotechnology and Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics, Inc. Stock News

As of December 9, 2025, Arrowhead Pharmaceuticals, Inc. had a $9.3 billion market capitalization, compared to the Biotechnology median of $223.1 million. Arrowhead Pharmaceuticals, Inc.’s stock is up 266.1% in 2025, up 18.8% in the previous five trading days and up 196.84% in the past year.

Currently, Arrowhead Pharmaceuticals, Inc. does not have a price-earnings ratio. Arrowhead Pharmaceuticals, Inc.’s trailing 12-month revenue is $829.4 million with a -0.2% net profit margin. As of December 9, 2025, Arrowhead Pharmaceuticals, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-3.164 per share for the current fiscal year. Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.

As of December 9, 2025, Nurix Therapeutics, Inc. had a $2.0 billion market cap, putting it in the 56th percentile of all stocks. Nurix Therapeutics, Inc.’s stock is up 3.8% in 2025, up 19.6% in the previous five trading days and up 3.12% in the past year.

Currently, Nurix Therapeutics, Inc. does not have a price-earnings ratio. Nurix Therapeutics, Inc.’s trailing 12-month revenue is $83.7 million with a -292.5% net profit margin. Year-over-year quarterly sales growth most recently was -37.3%. Analysts expect adjusted earnings to reach $-3.108 per share for the current fiscal year. Nurix Therapeutics, Inc. does not currently pay a dividend.

How We Compare Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Arrowhead Pharmaceuticals, Inc.	ARWR	F
Nurix Therapeutics, Inc.	NRIX	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Arrowhead Pharmaceuticals, Inc. has a Growth Score of 17, which is Very Weak. Nurix Therapeutics, Inc. has a Growth Score of 30, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics or Inc. is the better investment when it comes to sustainable growth.

Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
Arrowhead Pharmaceuticals, Inc.	ARWR	C
Nurix Therapeutics, Inc.	NRIX	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Arrowhead Pharmaceuticals, Inc. has a Quality Score of 59, which is Average. Nurix Therapeutics, Inc. has a Quality Score of 8, which is Very Weak.

The Quality Stock Winner: No Clear Winner

Neither Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics or Inc. is the better investment when it comes to quality.

Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Arrowhead Pharmaceuticals, Inc.	ARWR	F
Nurix Therapeutics, Inc.	NRIX	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Arrowhead Pharmaceuticals, Inc. has a Earnings Estimate Score of 20, which is Very Negative. Nurix Therapeutics, Inc. has a Earnings Estimate Score of 46, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics and Inc. Grades

In addition to Growth, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics or Inc. Stock?

Overall, Arrowhead Pharmaceuticals, Inc. stock has a Growth Score of 17, Estimate Revisions Score of 20 and Quality Score of 59.

Nurix Therapeutics, Inc. stock has a Growth Score of 30, Estimate Revisions Score of 46 and Quality Score of 8.

Comparing Arrowhead Pharmaceuticals, Inc., Nurix Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.